Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SINAPPS2: IVIG and Rituximab in Antibody-associated Psychosis
NCT03194815Phase 2Active, not recruiting
- Sponsor
- University of Cambridge
- Start
- Nov 2017
- Primary completion
- Apr 2027
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in psychosis and Autoimmune Encephalitis (AE) comparing Intravenous immunoglobulin and Rituximab with Placebo (2 arms). Primary endpoint: Time to start of symptomatic recovery at 18 months. Started Nov 2017; status: active, not recruiting.
02
Drugs
intravenous immunoglobulin Grituximab
03
Conditions
psychosisAutoimmune Encephalitis (AE)
Beyond the preview
Go deeper on NCT03194815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03194815.